There are 2934 resources available
Turning cold into hot tumours
Presenter: Aurélien Marabelle
Session: Next challenges for cancer immunotherapy
Resources:
Slides
Webcast
1900 - Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy
Presenter: Scott Tagawa
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant LBA54 and LBA55
Presenter: Ignacio Duran Martinez
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant 901O and 902O
Presenter: Yohann Loriot
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
Role of imaging follow-up
Presenter: Virginie Westeel
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
Role of patient reported outcome in patients' follow-up
Presenter: Paul van Schil
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
Patient perspective/expectations
Presenter: Regine Ihlen
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
Conclusions and perspectives
Presenter: Thierry Berghmans
Session: Beyond initial radical treatment of patients with lung cancer
Resources:
Slides
Webcast
1056 - Primary 2-year (yr) results of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Presenter: Reinhard Dummer
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
2898 - Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED)
Presenter: Dirk Schadendorf
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract